Letters
Good things come in threes (and sometimes fours): Update on renin–angiotensin–aldosterone system inhibitors and COVID-19
Kieran L. Quinn, Michael Fralick, Jonathan S. Zipursky and Nathan M. Stall
CMAJ June 01, 2020 192 (22) E611; DOI: https://doi.org/10.1503/cmaj.75720
Kieran L. Quinn
Clinical associate, Department of Medicine, University of Toronto; Division of General Internal Medicine and Geriatrics, Sinai Health System; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ont.
MD MScMichael Fralick
Assistant professor, Department of Medicine, University of Toronto; Division of General Internal Medicine and Geriatrics, Sinai Health System, Toronto, Ont.
MD PhDJonathan S. Zipursky
Clinical associate, Department of Medicine and Institute of Health Policy, Management and Evaluation, University of Toronto; Division of Clinical Pharmacology and Toxicology, Sunnybrook Health Sciences Centre, Toronto, Ont.
MDNathan M. Stall
Clinical associate, Department of Medicine, University of Toronto; Division of General Internal Medicine and Geriatrics, Sinai Health System; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ont.
MDIn this issue
Article tools
Good things come in threes (and sometimes fours): Update on renin–angiotensin–aldosterone system inhibitors and COVID-19
Kieran L. Quinn, Michael Fralick, Jonathan S. Zipursky, Nathan M. Stall
CMAJ Jun 2020, 192 (22) E611; DOI: 10.1503/cmaj.75720